Photo Credit: Magicmine

The following is a summary of “MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition,” published in the January 2024 issue of Oncology by Riedel, et al.

MET fusions are discussed rarely in NSCLC. Thus, there isn’t much data on the types of patients and how well they respond to treatment. For a study, researchers sought to present histopathologic data, clinical information about the patients, and treatment outcomes, such as the reaction to MET tyrosine kinase inhibitor (TKI) therapy in MET fusion-positive NSCLC. They talk about a group of nine people who all have MET fusions.

Out of these nine cases, two had already been recorded. Overall, 0.29% of the time, with a 95% CI of 0.15 to 0.55. The only type of cancer found was adenocarcinomas. The group was different regarding age, gender, and smoking status. Among them were KIF5B, TRIM4, ST7, PRKAR2B, and CAPZA2. There were also several different breakpoints. A MET TKI was given to four patients; two had partial reactions, one had steady disease, and one had a disease that got worse.

One patient had a BRAF V600E mutation, a form of acquired tolerance. Very rarely, MET fusions are the cause of cancer in NSCLC, and they mostly happen in adenocarcinomas. In terms of fusion partners and breakpoints, they are all different. MET TKI treatment can help people who have MET fusion.

Source: sciencedirect.com/science/article/abs/pii/S1556086423006664